Jiangzhong pharmaceutical: it is estimated that the total operating revenue in the first quarter of 2022 will be about 890 million yuan, with a year-on-year increase of about 30%
Jiangzhong pharmaceutical announced that according to the company's preliminary prediction, the total operating revenue in the first quarter of 2022 is expected to be about 890 million yuan, an increase of about 30% year-on-year; The net profit attributable to the parent company is expected to be about 180 million yuan, with a year-on-year increase of about 11%.
This text is a result of machine translation.
Related companies：
Briefing Mar 21, 2025 05:14 PM
· Technology
Shanghai to Launch Its First Direct Passenger Flight Route to a Central Asian Country in May
In-depth
Technology
China’s E-bike Brands Going Global: A Review of 26 Leading Players
With the global e-bike market continuing to expand, Chinese e-bike companies are gradually shifting from being a manufacturing powerhouse to becoming a meaningful force in global competition. This article reviews a group of Chinese e-bike players and examines their overseas positioning and market entry paths—looking at how Chinese brands are securing a foothold in the next wave of globalization.
Dec 19, 2025 02:56 PM
Briefing Oct 20, 2023 06:03 PM
· Technology
China’s OpenAI Challenger Zhipu AI Secures Over CNY 2.5 Billion to Step Further on Large-Scale Model
Jan 30, 2026 06:00 PM
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 05, 2023 07:33 PM
Briefing Apr 19, 2022 07:44 AM
· Healthcare
China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride capsule" has been approved
Briefing Nov 01, 2021 09:43 AM
· Technology
Semiconductor plate opened stronger
Technology
Pacini Completes RMB 1 Billion+ Series B Financing
Recently, PaXini Tech (帕西尼感知科技), a global leader in embodied perception-driven general intelligence, announced that it has completed a Series B financing round exceeding RMB 1 billion, bringing the company’s valuation to over RMB 10 billion.
Mar 09, 2026 02:37 PM
Healthcare
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
Briefing Aug 18, 2021 07:54 PM
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
Briefing Aug 02, 2021 06:01 PM
· Technology
Shennan circuit: it is proposed to raise no more than 2.55 billion yuan
See more
Read next
Insight
In-depth
Automotive · Analysis
Thinking of ASEAN as a single market is the biggest miscalculation for Chinese companies
Feb 19, 2026 12:00 PM
Insight
In-depth
Consumer Staples, Industrials, Communication
You're Invited: China's Innovation, Up Close
Feb 10, 2026 04:21 PM
Insight
In-depth
Automotive · Analysis
CES 2026 in Numbers | From Shenzhen to Las Vegas: Huaqiangbei’s Year-End Report
Jan 15, 2026 09:42 PM